Fierce Pharma

Mirum bags FDA approval for ultra-rare bone lesion disorder, heating up rivalry with Regeneron

In just over a month, the FDA has cleared not one, but two treatments for fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic condition that causes soft tissues to turn to bone. | Mirum ...
Fierce Pharma

Merck, Eisai’s Welireg-Lenvima combo lands FDA nod to jump the kidney cancer queue

Merck & Co. has scored an FDA approval for its blockbuster-to-be Welireg to move into second-line treatment of kidney cancer, ...
Fierce Pharma

Lundbeck to move US digs to Boston as it eyes bigger innovation frontiers

From its original U.S. home base in Deerfield, Illinois, Lundbeck now plans to relocate its local headquarters to Greater ...
Fierce Pharma

Fierce Pharma Week: A look at the biggest trends, campaigns and conversations

Fierce Pharma Week brought thousands of people to Philadelphia for four days of conversations about pharma marketing, ...
Fierce Pharma

Fierce Pharma Asia—Lilly’s $3.35B InnoCare deal; Korea’s breakthrough; China’s 5-year biotech plan

Eli Lilly and InnoCare Pharma inked a multi-target deal potentially worth $3.35 billion. The FDA has doled out the first approval for a novel cancer drug from a Korean company. | Eli Lilly and ...
Fierce Pharma

Eli Lilly blasted for ‘promotional and emotive’ language in GLP-1 press release

A U.K. watchdog has scolded Eli Lilly over a press release the drugmaker sent to the BBC, arguing that its use of ...
Fierce Pharma

Boehringer Ingelheim offloads Shanghai CDMO to local antibody developer

Boehringer Ingelheim is bidding adieu to its biologics contract manufacturing unit in China, inking a small-scale deal that gives local developer Raas Blood Products an established production base for ...
Fierce Pharma

GSK slammed for ‘grossly misleading’ and ‘totally unacceptable’ behavior

GSK showed a “totally unacceptable” lack of transparency in its interactions wi | GSK showed a “totally unacceptable” lack of transparency in its interactions with the PMCPA, the U.K. self-regulatory ...
Fierce Pharma

Elevar wins FDA nod for bile duct cancer drug Lyrfigtu, a first for a Korean firm

The FDA came to Elevar Therapeutics bearing gift ahead of the mid-autumn festival. | The FDA has greenlighted Elevar’s FGFR2-selective inhibitor Lyrfigtu in bile duct cancer, making it the first novel ...
Fierce Pharma

Otsuka JV recalls one lot of sodium chloride over labeling issue

Otsuka ICU Medical, a joint venture from Japan’s Otsuka Pharmaceutical Factory, issued a voluntary recall of one lot of 0.9% sodium chloride injection for IV due to a possible mix-up of labels.
Fierce Pharma

Biogen springs social media kidney health campaign with Olympic gymnast Suni Lee

Biogen has teamed with gymnast Suni Lee for a campaign, leveraging the Olympic gold medalist’s health journey and social media audience to vault deeper into kidney health awareness.  | Biogen has ...
Fierce Pharma

Novo is open to a direct listing on the New York Stock Exchange

Novo  may be willing to transition some of its shares to the New York Stock Exchange in an effort to woo U.S. investors.  | The Ozempic and Wegovy maker's CEO said he's open to a direct listing of ...